Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
947.4 INR | -0.40% | +2.74% | +37.46% |
04-26 | Weak March Quarter Earnings Weigh Down Indian Equities on Friday | MT |
04-26 | Zydus Lifesciences Gets US FDA's Final Approval for Generic Acne Cream | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With a 2024 P/E ratio at 26.43 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+37.46% | 11.43B | B | ||
+19.62% | 43.34B | B- | ||
+20.44% | 21.96B | B+ | ||
+10.86% | 14.09B | - | ||
+13.07% | 13.64B | B+ | ||
-8.59% | 6.86B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+8.46% | 5.22B | B+ | ||
-4.29% | 4.71B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ZYDUSLIFE Stock
- Ratings Zydus Lifesciences Limited